A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs LY 3076226 (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2018.
    • 11 Apr 2017 Planned number of patients changed from 65 to 37.
    • 08 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top